Omzotirome

Omzotirome
Identifiers
	IUPAC name 3-(4-((7-Hydroxy-6-methyl-2,3-dihydro-1H-inden-4-YL)methyl)-3,5-dimethyl-1H-pyrazol-1-yl)propanoic acid;
CAS Number	1092551-88-6;
PubChem CID	25125529;
DrugBank	DB16046;
ChemSpider	28534873;
UNII	B93608MTGW;
ChEMBL	ChEMBL4297445;
CompTox Dashboard (EPA)	DTXSID70148862 ;
Chemical and physical data
Formula	C19H24N2O3
Molar mass	328.412 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C2CCCC2=C1O)CC3=C(N(N=C3C)CCC(=O)O)C;
	InChI InChI=1S/C19H24N2O3/c1-11-9-14(15-5-4-6-16(15)19(11)24)10-17-12(2)20-21(13(17)3)8-7-18(22)23/h9,24H,4-8,10H2,1-3H3,(H,22,23); Key:OFUOCIUIWKDKPA-UHFFFAOYSA-N;

Omzotirome (INN), formerly codenamed TRC-150094, is a thyromimetic drug which acts as a metabolic modulator which restores metabolic flexibility. It has been shown to improve insulin resistance and hyperglycemia, and is in Phase III human clinical trials for the treatment of Cardiometabolic-Based Chronic Disease (CMBCD) by improving dysglycemia, dyslipidemia and hypertension.^[1]^[2]^[3]^[4]^[5]

References

^ Cioffi F, Zambad SP, Chhipa L, Senese R, Busiello RA, Tuli D, et al. (September 2010). "TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet". FASEB Journal. 24 (9): 3451–61. doi:10.1096/fj.10-157115. PMID 20453112. S2CID 39205547.
^ Silvestri E, Glinni D, Cioffi F, Moreno M, Lombardi A, de Lange P, et al. (July 2012). "Metabolic effects of the iodothyronine functional analogue TRC150094 on the liver and skeletal muscle of high-fat diet fed overweight rats: an integrated proteomic study". Molecular BioSystems. 8 (7): 1987–2000. doi:10.1039/c2mb25055a. PMID 22543897.
^ van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, et al. (2014). "The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial". PLOS ONE. 9 (2): e86890. Bibcode:2014PLoSO...986890V. doi:10.1371/journal.pone.0086890. PMC 3931609. PMID 24586256.
^ Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F (March 2014). "Thyroid hormone analogues and derivatives: Actions in fatty liver". World Journal of Hepatology. 6 (3): 114–29. doi:10.4254/wjh.v6.i3.114. PMC 3959112. PMID 24672641.
^ Clinical trial number NCT03254446 for "Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension. Torrent Pharmaceuticals Ltd." at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Cioffi F, Zambad SP, Chhipa L, Senese R, Busiello RA, Tuli D, et al. (September 2010). "TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet". FASEB Journal. 24 (9): 3451–61. doi:10.1096/fj.10-157115. PMID 20453112. S2CID 39205547.

[2] Silvestri E, Glinni D, Cioffi F, Moreno M, Lombardi A, de Lange P, et al. (July 2012). "Metabolic effects of the iodothyronine functional analogue TRC150094 on the liver and skeletal muscle of high-fat diet fed overweight rats: an integrated proteomic study". Molecular BioSystems. 8 (7): 1987–2000. doi:10.1039/c2mb25055a. PMID 22543897.

[3] van der Valk F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, et al. (2014). "The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial". PLOS ONE. 9 (2): e86890. Bibcode:2014PLoSO...986890V. doi:10.1371/journal.pone.0086890. PMC 3931609. PMID 24586256.

[4] Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F (March 2014). "Thyroid hormone analogues and derivatives: Actions in fatty liver". World Journal of Hepatology. 6 (3): 114–29. doi:10.4254/wjh.v6.i3.114. PMC 3959112. PMID 24672641.

[5] Clinical trial number NCT03254446 for "Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension. Torrent Pharmaceuticals Ltd." at ClinicalTrials.gov

[1]

[2]

[3]

[4]

[5]